BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Oct 9, 2019
Politics, Policy & Law

Long-term data help two drugs sway ICER in drug price report

How long-term data helped justify Revlimid, Genovya price increases to ICER where other drugs faltered
BioCentury | May 1, 2018
Company News

HCV drug sales drag down Gilead's 1Q18 earnings

BioCentury | May 3, 2017
Company News

Gilead HCV sales continue to weaken

BioCentury | Feb 8, 2017
Company News

Gilead HCV outlook souring

BioCentury | Nov 1, 2016
Financial News

Gilead maintains guidance as HCV sales shrink

BioCentury | Apr 18, 2016
Company News

Gilead sales and marketing update

BioCentury | Jan 6, 2016
Clinical News

Gilead's TAF non-inferior to Viread in HBV

BioCentury | Dec 7, 2015
Clinical News

Tenofovir alafenamide fumarate regulatory update

Items per page:
1 - 10 of 13